Scholar Rock's Chief Scientific Officer Mo Qatanani sold 14,898 shares on January 22, 2026, for approximately $695,938 as part of a pre-planned Rule 10b5-1 trading plan. The sale reduced his direct ownership to 85,660 shares (0.08% of outstanding shares). The company plans to launch its key product candidate apitegromab in U.S. and European markets in 2026, positioning it as a potential treatment for spinal muscular atrophy.

Commodore Capital fully exited its position in Scholar Rock, selling approximately 1.5 million shares in Q3, representing a $51 million transaction. The biotech company is preparing to resubmit its apitegromab biologics license application after a previous FDA rejection.

The FDA approved Novartis' Itvisma, a gene replacement therapy for spinal muscular atrophy (SMA), which can treat patients two years and older by addressing the genetic root cause of the disease with a one-time fixed dose.

Scholar Rock's stock dropped over 13% after the FDA designated a Catalent Indiana manufacturing facility as Official Action Indicated (OAI), following a previous FDA rejection of its spinal muscular atrophy drug application.

Bank of America analyst Tazeen Ahmad initiated coverage on Scholar Rock, setting a buy rating with a $53 price target, which drove the stock up 6%. The analyst is particularly interested in the company's investigational spinal muscular atrophy (SMA) drug apitegromab.

Multiple stocks saw significant gains on Friday, with Crinetics Pharmaceuticals leading the pack after FDA approval, while other companies like BlackBerry, Perpetua Resources, and Scholar Rock also experienced notable stock price increases.

Biotech stock Scholar Rock (SRRK) jumped nearly 3% on Wednesday after a positive analyst note from Piper Sandler's Allison Bratzel. Bratzel believes the company's lead drug candidate, apitegromab, is undervalued and could see significant upside if approved for treating spinal muscular atrophy (SMA).

Scholar Rock, a clinical-stage drugmaker, has developed a treatment candidate called apitegromab that prevents muscle loss. Results from a late-stage clinical trial suggest apitegromab can become a blockbuster-companion treatment for patients with a rare muscle-wasting disorder, leading to a 364% surge in the company's stock price.

This article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events.

Stay informed with Seeking Alpha's Stocks to Watch newsletter, featuring previews of upcoming key events in the stock market, including upcoming IPOs, investor days and earnings reports.

Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to preserve muscle loss. The analysis focuses on the potential of their lead program, apitegromab, for Spinal Muscular Atrophy (SMA), which is currently in a Phase 3 trial (SAPPHIRE) with data expected in Q4 2024.  Apitegromab benefits from robust Phase 2 data (TOPAZ) and shows promise as an add-on therapy to existing treatments for SMA. The analyst commences coverage of Scholar Rock with a Strong Buy rating ...Full story available on Benzinga.com

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. Shares of NIO Inc. (NYSE: NIO) rose during Tuesday’s session following upbeat quarterly results. NIO reported fourth-quarter revenue of 17.10 billion yuan ($2.41 billion), up by 6.5% year-over-year and down by 10.3% from the previous quarter. Analysts, on average, estimated revenue of $2.29 billion for the quarter. Excluding share-based compensation expenses, the company reported an adjusted loss of (2.81) yuan or ($0.39) compared to (3.07) yuan in the year-ago quarter and (2.28) yuan in the third quarter of 2023. Analysts had called for a loss of $(0.51) per share. NIO shares gained 3.6% to $5.52 on Tuesday. Here are some other big stocks recording gains in today’s session. Apogee Therapeutics, Inc. (NASDAQ: APGE) shares gained 41.6% to $59.10 after the company announced interim results from its Phase 1 healthy volunteer trial for APG777. Also, the company reported FY23 financial results. Dave ...